<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314987</url>
  </required_header>
  <id_info>
    <org_study_id>17.1067</org_study_id>
    <nct_id>NCT03314987</nct_id>
  </id_info>
  <brief_title>Carnosine and Cardiovascular Disease</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Nucleophilic Defense Against PM Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carnosine is a naturally occurring peptide found in high levels in skeletal muscle and the
      brain and is also available commercially as a dietary supplement. Since carnosine has
      anti-oxidant properties and air pollution exposure induces a state of oxidative stress, the
      purpose of this study is to see if those taking carnosine as a dietary supplement are
      protected from air pollution-induced oxidative stress and adverse cardiovascular outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      240 subjects from the Louisville Healthy Heart Study (LHHS) will be invited to participate in
      a study evaluating the efficacy of carnosine in preventing particulate matter air pollution
      (PM2.5)-induced vascular injury. This is a placebo controlled, randomized, double-blind,
      Phase II interventional trial. Subjects will be randomized to receive placebo or carnosine
      between May 1 and August 31, when the levels of PM2.5.are highest in Louisville (average
      between 10-20 mg/m3). In each of the 2 study years, the participants will take maximal
      tolerable dose of carnosine - 2 tablets every day in the morning, 500 mg each, shown to be
      effective in diabetic nephropathy. Carnosine levels and cardiovascular outcomes will be
      measured before the intervention and at 2 additional times (till the end of August) to assess
      efficacy of intervention. Thus, all participants will be on carnosine for 4 months and
      carnosine levels and vascular function will be examined so that the investigators will have
      three measurements from each participant at high and low levels of PM2.5 exposure. At each
      study visit, collected blood samples will be used to measure indices of CVD risk (LDL, HDL,
      cholesterol, total cholesterol, triglycerides, glucose, HbA1c, serum creatinine and
      fibrinogen) and biomarkers of vascular injury and inflammation. In addition, the
      investigators will assess vascular function (flow mediated dilation, reactive hyperemia, or
      arterial stiffness) and measure biomarkers of exposure (cotinine, and 18 VOC metabolites,
      carnosine conjugates, creatinine) and oxidative stress (isoprostanes) in urine samples.
      Statistical mixed effects models to evaluate the association between PM2.5 and vascular
      dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial progenitor cells</measure>
    <time_frame>3 months</time_frame>
    <description>circulating stem cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>3 months</time_frame>
    <description>index of arterial function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial microparticles</measure>
    <time_frame>3 months</time_frame>
    <description>index of endothelial damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet monocyte aggregates</measure>
    <time_frame>3 months</time_frame>
    <description>index of platelet activation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carnosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnosine</intervention_name>
    <description>a naturally occurring di-peptide</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>an identically appearing supplement</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  individuals between 25-65 years of age of either gender and all ethnicities,

          -  either gender and all ethnicities

          -  carnosine levels below the median value of the population

          -  must be able to swallow tablets

        Exclusion Criteria:

          -  individuals with carnosine levels in the upper half of the population

          -  those with active treatment for alcohol and drug abuse

          -  those using immunosuppressant agents

          -  those with conditions known to effect peripheral blood cell counts and bone marrow
             function such as malignancies, organ transplant, renal replacement therapy, type 1
             diabetes, untreated thyroid disease, anemia, acute infections, HIV infection,
             hepatitis, and unhealed wounds

          -  those on hormone replacement therapy or medications affecting bone marrow function or
             peripheral blood cell counts

          -  those unwilling or unable to provide informed consent

          -  pregnant or lactating women

          -  prisoners and other vulnerable populations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy E O'Toole, Ph.D.</last_name>
    <phone>502-852-5886</phone>
    <email>teotoo01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Beatty, R.N.</last_name>
    <phone>502-852-6167</phone>
    <email>karen.beatty@louisville.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>O'Toole TE, Hellmann J, Wheat L, Haberzettl P, Lee J, Conklin DJ, Bhatnagar A, Pope CA 3rd. Episodic exposure to fine particulate air pollution decreases circulating levels of endothelial progenitor cells. Circ Res. 2010 Jul 23;107(2):200-3. doi: 10.1161/CIRCRESAHA.110.222679. Epub 2010 Jul 1.</citation>
    <PMID>20595651</PMID>
  </reference>
  <results_reference>
    <citation>Barski OA, Xie Z, Baba SP, Sithu SD, Agarwal A, Cai J, Bhatnagar A, Srivastava S. Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1162-70. doi: 10.1161/ATVBAHA.112.300572. Epub 2013 Apr 4.</citation>
    <PMID>23559625</PMID>
  </results_reference>
  <results_reference>
    <citation>Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O'Toole T. Exposure to Fine Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation. Circ Res. 2016 Nov 11;119(11):1204-1214. doi: 10.1161/CIRCRESAHA.116.309279. Epub 2016 Oct 25.</citation>
    <PMID>27780829</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Timothy Edward O'Toole</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>air pollution</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>intervention</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

